Medicare AdvantageCoverageMedium impact
MA08.099b, Burosumab-twza (Crysvita®)
Independence Blue Cross·Endocrinology, Pediatrics, Nephrology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.099b for Burosumab-twza (Crysvita®) has been reissued effective May 28, 2025. This is a pharmacy policy update that may affect coverage or billing requirements for this specialty drug used to treat rare phosphate disorders.
Action Required
By May 28, 2025: Billing team should review the updated MA08.099b policy for Burosumab-twza (Crysvita®) at the provided URL to identify any changes to prior authorization, coverage criteria, or billing requirements for Medicare Advantage patients. Update billing protocols and staff training as needed based on policy changes.